Results 171 to 180 of about 146,093 (222)

Maximizing blood pressure lowering effects: a review of drug class comparisons and rationale for combination approaches. [PDF]

Front Cardiovasc Med
Yang Y, Wan F, Xu J, Mei Deng H, Pan P.
europepmc   +1 more source

Association Between Pre-hospital Medication Use and Outcomes in Patients Hospitalized for COVID-19 Pneumonia: A Multicenter Observational Study in the Netherlands. [PDF]

Cureus
Li L, Goris-de Geus J, de Leeuw I, Kanits F, Zegers J, van Zadelhoff A, Buenen N, Rettig TCD, Hoir MPL, Duijzer G, Geleijnse JM, Endeman H.   +11 more
europepmc   +1 more source

Angiotensin II type 1 receptor blockers lower IOP in mice and reduce TGFβ signaling in retinal ganglion cells

, 2017
Ralph J. Hazlewood, John Kuchtey, Rachel W. Kuchtey   +2 more
openalex   +1 more source

Plasma aldosterone is low in patients hospitalized with COVID-19 and not associated with changes in serum potassium levels: <i>post hoc</i> observational analyses of clinical trial data. [PDF]

Front Endocrinol (Lausanne)
Krenn S, Hödlmoser S, Kurnikowski A, Jorge P, Eskandary F, Heinze G, Hecking M, Reindl-Schwaighofer R.   +7 more
europepmc   +1 more source

Differences in clinical profiles and cancer incidence among patients with type 2 diabetes in primary care: Comparison between multidisciplinary and usual management. [PDF]

J Multimorb Comorb
Yau STY, Hung CT, Leung EYM, Lee A, Yeoh EK.   +4 more
europepmc   +1 more source

Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages.

JAMA Health Forum
Callaway Kim K, Roberts ET, Donohue JM, Sabik LM, Good CB, Devine JW, Tadrous M, Suda KJ.   +7 more
europepmc   +1 more source

Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers. [PDF]

Int J Mol Sci
Chatzipieris FP, Mavromoustakou K, Matsoukas JM, Mavromoustakos T.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers

Current Pharmaceutical Design, 2013
Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies
Satoshi, Imaizumi, Shin-ichiro, Miura, Eiji, Yahiro, Yoshinari, Uehara, Issei, Komuro, Keijiro, Saku   +5 more
openaire   +3 more sources

Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers

Acta Diabetologica, 2005
Vascular protection is key to reducing the morbidity associated with diabetes. Angiotensin II is known to exert a variety of deleterious effects on the vasculature, and this is likely to be a major explanation of the protective benefits observed with blockade of the renin-angiotensin-aldosterone system (RAAS).
U, Kintscher, T, Unger
openaire   +3 more sources